BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 15229616)

  • 1. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hairy-cell leukemia: current views.
    Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
    Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
    Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
    Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
    Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hairy cell leukemia 1992.
    Spielberger RT; Golomb HM
    Leukemia; 1992 Nov; 6 Suppl 4():142-6. PubMed ID: 1279327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].
    Pawelski S
    Acta Haematol Pol; 1995; 26(2):139-43. PubMed ID: 7653218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.
    Golomb HM; Dodge R; Mick R; Budman D; Hutchison R; Horning SJ; Schiffer CA
    Leukemia; 1994 Dec; 8(12):2037-40. PubMed ID: 7807991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
    Seymour JF; Talpaz M; Kurzrock R
    Leukemia; 1997 Jan; 11(1):42-7. PubMed ID: 9001417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.